About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Stroke is a medical emergency and a leading cause of death and disability worldwide affecting millions of subjects. In this context the Neurovascular Research Laboratory was created in 2001 focused in stroke research from a basic and translational perspective, covering all stages of the disease: from prevention and treatment, to recovery.
Nowadays our team is composed by a highly motivated group of researchers including clinical and basic scientists, with group leaders involved in National and International projects with public or private research funding on biomarkers for clinical decision making in stroke, the presence of silent infarctions, the assessment of cognition and cognitive decline, developing experimental models of cerebral ischemia testing new treatments complementary to reperfusion, and developing studies on cerebral amyloid angiopathy, tissue neurorepair or post-stroke rehabilitation.
Complementary studies on vascular dementia and Alzheimer disease related to amyloid-beta protein have also been encompassed as part of our research in the last years.
The TOUCH MSCA-COFUND doctoral training programme, led by UAB and focusing on the field of mental health, has opened its first call for applications, offering 13 doctoral positions.
The Cardiovascular Diseases and Neurovascular Diseases groups at VHIR will investigate new therapeutic strategies for heart failure, nanomedicine in stroke and the prevention of cardiovascular toxicity in the case of oncological treatments.
La recerca és fonamental per contrarestar els efectes de la pol·lució, que segons l’AEMPS, va ser la causa de més de 300.000 morts prematures a la UE el 2020.
